09:58 AM EST - Eupraxia Pharmaceuticals Inc. : Has initiated its Phase 3 development program for EP-104IAR, the Company's lead drug candidate for the treatment of osteoarthritis of the knee, following completion of its End-of-Phase 2 meeting with the U.S. Food & Drug Administration. Eupraxia Pharmaceuticals Inc.
shares T.EPRX are trading up $0.34 at $6.19.
